StockNews.AI
VYGR
StockNews.AI
181 days

Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors

1. Kirby McInerney LLP is investigating Voyager Therapeutics for potential legal violations. 2. Voyager announced it's reassessing gene therapy for ALS due to subpar data. 3. They will not file IND application for VY9323 as planned. 4. Voyager's stock fell 20% following recent announcements.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The investigations and poor data have severely impacted investor confidence, historically leading to price drops.

How important is it?

The investigation could lead to legal penalties, which would directly impact VYGR's future.

Why Short Term?

Immediate legal investigations can affect stock price quickly, as seen in past similar cases.

Related Companies

VYGR
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR). The investigation concerns whether Voyager and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On February 11, 2025, Voyager issued a press release “announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)”, stating that “[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting a narrowed therapeutic window.” Voyager further stated that it “no longer anticipates filing an investigational new drug (IND) application for VY9323 in mid-2025.” On this news, the price of Voyager shares declined by $1.11 per share, or approximately 20%, from $5.32 per share on February 10, 2025, to close at $4.41 on February 11, 2025. If you purchased or otherwise acquired Voyager securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out the form below to discuss your rights or interests with respect to these matters without any cost to you. [CONTACT US] Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. ContactsKirby McInerney LLPThomas W. Elrod, Esq.212-699-1180https://www.kmllp.cominvestigations@kmllp.com

Related News